First OTC Low-Dose Brimonidine Eye Drop Approved for Ocular Redness

Share this content:

The Food and Drug Administration (FDA) has approved Lumify 0.025%, the first over-the-counter low-dose brimonidine tartrate ophthalmic solution for the treatment of ocular redness. 

Brimonidine, a selective alpha-2 adrenergic receptor agonist, works by selectively constricting the veins in the eye, increasing the availability of oxygen to surrounding tissue and reducing the likelihood of rebound redness, often associated with non-selective redness reducers. In clinical studies, low-dose brimonidine showed 95% symptom improvement at 1 minute, and reduced redness for up to 8 hours. 

Brimonidine is already approved in higher doses as a prescription eye drop for the treatment of intraocular pressure reduction in glaucoma patients.

Lumify is expected to be available from Bausch + Lomb in the second quarter of 2018.

For more information visit Bausch.com.

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




More in Home

Meds for Opioid Use Disorder May Reduce Mortality in OD Survivors

Meds for Opioid Use Disorder May Reduce Mortality ...

Minority of opioid overdose survivors receive MOUD; buprenorphine, MMT linked to reduced mortality

Pharmacists Are Well Placed to Improve Adult Vaccination Rates

Pharmacists Are Well Placed to Improve Adult Vaccination ...

Pharmacies can address cost barriers to vaccination by providing vaccines at lower cost

Single Blood Sample Test May Help ID Undiagnosed Diabetes

Single Blood Sample Test May Help ID Undiagnosed ...

Single-sample confirmatory definition associated with high positive predictive value

is free, fast, and customized just for you!




Already a member?

Sign In Now »